Cargando…

Usefulness of cardiac biomarkers for prognosis of better outcomes in chronic heart failure: Retrospective 18-year follow-up study

Brain natriuretic peptide is an established, surrogate follow-up marker, strongly correlated with heart failure severity. Several other biomarkers and tests are useful for assessing the prognosis of patients with HF, such as oxidized low-density lipoprotein antibodies and C-reactive protein. Some in...

Descripción completa

Detalles Bibliográficos
Autores principales: Charach, Gideon, Grosskopf, Itamar, Galin, Leonid, Robinson, Eyal, Hershenson, Roy, Charach, Lior
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7870268/
https://www.ncbi.nlm.nih.gov/pubmed/33592824
http://dx.doi.org/10.1097/MD.0000000000023464
_version_ 1783648784861888512
author Charach, Gideon
Grosskopf, Itamar
Galin, Leonid
Robinson, Eyal
Hershenson, Roy
Charach, Lior
author_facet Charach, Gideon
Grosskopf, Itamar
Galin, Leonid
Robinson, Eyal
Hershenson, Roy
Charach, Lior
author_sort Charach, Gideon
collection PubMed
description Brain natriuretic peptide is an established, surrogate follow-up marker, strongly correlated with heart failure severity. Several other biomarkers and tests are useful for assessing the prognosis of patients with HF, such as oxidized low-density lipoprotein antibodies and C-reactive protein. Some inflammatory cells, including monocytes, lymphocytes, and neutrophils, are involved in coronary heart disease and may be useful for prognosis also. This study assessed the potential usefulness of various laboratory biomarkers in predicting long-term outcomes and hospitalization among a cohort of outpatients with chronic, advanced HF. This retrospective, 18-year follow-up study included all patients admitted to the Heart Failure Outpatient Unit in our tertiary care medical center from 2000 through 2001 due to chronic HF. Excluded were patients with malignant disease, severe stroke, active inflammatory disease, or infection. At the first visit, blood was sampled for routine analysis and biomarkers NT-proBNP, C-reactive protein, myeloperoxidase, heat shock protein, and antibodies to oxidized low density lipoprotein. left ventricular ejection fraction and New York Heart Association class class were also established. Patients were followed every 3 months. Study endpoints were mortality or first hospitalization. Among 305 study patients, HF duration ranged from 2 months to 18 years. Mean follow-up was 9.1 ± 6 years. Mean time to first hospitalization was 60 ± 58.1 months, median = 38 (range 0–179). Mortality rate was 41%. Regression analysis showed New York Heart Association class, lymphocyte count and alkaline phosphatase were independent predictors of survival, with hazard ratios of 1.0, 0.973, and 1.006, respectively (P < .05). N-terminal pro-B-type natriuretic peptide, alkaline phosphatase, and lymphocyte count are important prognostic predictors for very long-term follow-up among patients with chronic HF.
format Online
Article
Text
id pubmed-7870268
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-78702682021-02-10 Usefulness of cardiac biomarkers for prognosis of better outcomes in chronic heart failure: Retrospective 18-year follow-up study Charach, Gideon Grosskopf, Itamar Galin, Leonid Robinson, Eyal Hershenson, Roy Charach, Lior Medicine (Baltimore) 3400 Brain natriuretic peptide is an established, surrogate follow-up marker, strongly correlated with heart failure severity. Several other biomarkers and tests are useful for assessing the prognosis of patients with HF, such as oxidized low-density lipoprotein antibodies and C-reactive protein. Some inflammatory cells, including monocytes, lymphocytes, and neutrophils, are involved in coronary heart disease and may be useful for prognosis also. This study assessed the potential usefulness of various laboratory biomarkers in predicting long-term outcomes and hospitalization among a cohort of outpatients with chronic, advanced HF. This retrospective, 18-year follow-up study included all patients admitted to the Heart Failure Outpatient Unit in our tertiary care medical center from 2000 through 2001 due to chronic HF. Excluded were patients with malignant disease, severe stroke, active inflammatory disease, or infection. At the first visit, blood was sampled for routine analysis and biomarkers NT-proBNP, C-reactive protein, myeloperoxidase, heat shock protein, and antibodies to oxidized low density lipoprotein. left ventricular ejection fraction and New York Heart Association class class were also established. Patients were followed every 3 months. Study endpoints were mortality or first hospitalization. Among 305 study patients, HF duration ranged from 2 months to 18 years. Mean follow-up was 9.1 ± 6 years. Mean time to first hospitalization was 60 ± 58.1 months, median = 38 (range 0–179). Mortality rate was 41%. Regression analysis showed New York Heart Association class, lymphocyte count and alkaline phosphatase were independent predictors of survival, with hazard ratios of 1.0, 0.973, and 1.006, respectively (P < .05). N-terminal pro-B-type natriuretic peptide, alkaline phosphatase, and lymphocyte count are important prognostic predictors for very long-term follow-up among patients with chronic HF. Lippincott Williams & Wilkins 2021-02-05 /pmc/articles/PMC7870268/ /pubmed/33592824 http://dx.doi.org/10.1097/MD.0000000000023464 Text en Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0
spellingShingle 3400
Charach, Gideon
Grosskopf, Itamar
Galin, Leonid
Robinson, Eyal
Hershenson, Roy
Charach, Lior
Usefulness of cardiac biomarkers for prognosis of better outcomes in chronic heart failure: Retrospective 18-year follow-up study
title Usefulness of cardiac biomarkers for prognosis of better outcomes in chronic heart failure: Retrospective 18-year follow-up study
title_full Usefulness of cardiac biomarkers for prognosis of better outcomes in chronic heart failure: Retrospective 18-year follow-up study
title_fullStr Usefulness of cardiac biomarkers for prognosis of better outcomes in chronic heart failure: Retrospective 18-year follow-up study
title_full_unstemmed Usefulness of cardiac biomarkers for prognosis of better outcomes in chronic heart failure: Retrospective 18-year follow-up study
title_short Usefulness of cardiac biomarkers for prognosis of better outcomes in chronic heart failure: Retrospective 18-year follow-up study
title_sort usefulness of cardiac biomarkers for prognosis of better outcomes in chronic heart failure: retrospective 18-year follow-up study
topic 3400
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7870268/
https://www.ncbi.nlm.nih.gov/pubmed/33592824
http://dx.doi.org/10.1097/MD.0000000000023464
work_keys_str_mv AT charachgideon usefulnessofcardiacbiomarkersforprognosisofbetteroutcomesinchronicheartfailureretrospective18yearfollowupstudy
AT grosskopfitamar usefulnessofcardiacbiomarkersforprognosisofbetteroutcomesinchronicheartfailureretrospective18yearfollowupstudy
AT galinleonid usefulnessofcardiacbiomarkersforprognosisofbetteroutcomesinchronicheartfailureretrospective18yearfollowupstudy
AT robinsoneyal usefulnessofcardiacbiomarkersforprognosisofbetteroutcomesinchronicheartfailureretrospective18yearfollowupstudy
AT hershensonroy usefulnessofcardiacbiomarkersforprognosisofbetteroutcomesinchronicheartfailureretrospective18yearfollowupstudy
AT charachlior usefulnessofcardiacbiomarkersforprognosisofbetteroutcomesinchronicheartfailureretrospective18yearfollowupstudy